Bosnian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Mayo Clinic Proceedings 1992-Jun

Leiomyosarcoma of the stomach: determinants of long-term survival.

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Veza se sprema u međuspremnik
G Farrugia
C H Kim
C S Grant
A R Zinsmeister

Ključne riječi

Sažetak

To determine factors associated with a favorable long-term prognosis in gastric leiomyosarcoma, we retrospectively reviewed the medical records of 93 Mayo Clinic patients with this biopsy-proven tumor diagnosed during the 25-year period from 1964 through 1988. Six patients who had Carney's triad (gastric epithelioid leiomyosarcoma, pulmonary chondroma, and functioning extra-adrenal paraganglioma) were excluded from data analysis. The other 87 patients participated in follow-up until death or for a median duration of 5.8 years for those who were alive at the conclusion of the study. The most common symptoms at the time of initial assessment were abdominal pain (51%), melena (36%), and weight loss (16%). Most often, the tumor was located in the greater curvature (25%), fundus (20%), or lesser curvature (16%) of the stomach. Two percent of patients had tumors at multiple sites. All 87 gastric leiomyosarcomas were histologically confirmed; 38% were grade 1, 37% were grade 2, and 25% were either grade 3 or grade 4. Metastatic involvement was noted in 15% of patients at the time of diagnosis. The 5- and 10-year survival rates were 45% and 34%, respectively, and the 5- and 10-year tumor recurrence rates were 57% and 65%, respectively. Variables that were associated with long-term survival were low histologic grade of the tumor, absence of metastatic lesions, and small tumor size (P < 0.01); variables such as site of the tumor, initial symptoms, age, and sex provided no significant additional prognostic information.

Pridružite se našoj
facebook stranici

Najkompletnija baza ljekovitog bilja potpomognuta naukom

  • Radi na 55 jezika
  • Biljni lijekovi potpomognuti naukom
  • Prepoznavanje biljaka po slici
  • Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
  • Pročitajte naučne publikacije povezane sa vašom pretragom
  • Pretražite ljekovito bilje po učincima
  • Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima

Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Sve informacije temelje se na objavljenim naučnim istraživanjima

Google Play badgeApp Store badge